SEC Form 4 · accession 0001209191-17-042875
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ali Behbahani
Director
Period of report
Jul 3, 2017
Accepted (ET)
Jul 3, 2017 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Ordinary SharesF1 | $0.75 | Jul 3, 2017 | A | 220,788 | A | Jul 3, 2018 | Jul 3, 2027 | Ordinary Shares | 220,788 | 220,788 | D |
Explanation of responses
- F1The exercise price was converted from GBP0.58 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.